Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

ALNYLAM PHARMACEUTICALS, INC.

Filed by TIBER CREEK GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 18, 2025
Income
$60,000.00
Expenses
Not reported
Filing UUID
bc707321-a2f3-4e1e-8e61-63f3ee20bf3f
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Literal federal measure citations: H.R. 1672

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.